News: Medicine

View:

2007

 

Found press releases

 

Aerocrine enters distribution agreement with Phadia in France

12/20/2007 4:00 AM EST  -   Aerocrine
SOLNA – 20 December, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Phadia France.
As of 1 January 2008, Aerocrine has granted Phadia the right to market and sell NIOX MINO® on the French market. Phadia, a world-leader within allergy diagnostics, already sells Aerocrine products
in Spain.

In France about 4 million people have...

Q-Med´s new CFO appointed

12/18/2007 7:02 AM EST  -   Q-Med
Alexander Kotsinas will be Q-Med’s new CFO. He takes up his appointment February 1, 2008.

- “It is not without pride that we can announce that Alexander Kotsinas will be joining Q-Med’s senior management team in the role of company CFO. Alexander has experience or working in fast-growing, entrepreneurial organizations and has succeeded very well, with the support of good judgement and a solid education. We have...

Getinge Capital Markets Day 2008

12/18/2007 3:00 AM EST  -   Getinge Group
On January 30, 2008 Getinge will host its annual Capital Markets Day at Grand Hotel in
Stockholm. Attendees will receive an update on current activities and plans for the future.

The conference is intended for professional analysts, investors and media representatives.

Date and time:
Wednesday 30 January 2008 at 10.00 a.m.to about 17.00 p.m.
Registration from 09.30

Place:
Grand Hotel Stockholm

RSVP...

COMPASS® receives FDA clearance and is launched

12/18/2007 2:00 AM EST  -   RaySearch Laboratories
RaySearch Laboratories AB (publ.) and IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced today that the new dosimetry solution COMPASS® has received 510(k) clearance by the FDA and that it has been launched on the worldwide market through IBA’s business unit IBA Dosimetry.

COMPASS® is a state-of-the-art solution for quality assurance in radiotherapy that has been developed in joint...

Orexo´s partner Endo announces positive results from interim analysis of Rapinyl...

12/17/2007 7:32 AM EST  -   Orexo
Orexo´s licensing partner for Rapinyl ™ in North America announced today positive results from the previously announced, planned interim statistical analysis of a Phase III, placebo-controlled, double-blind trial of its development product, Rapinyl ™. The data from the analysis of 61 patients demonstrated that Rapinyl ™ met its primary endpoint, the Sum of Pain Intensity Difference from baseline to 30 minutes (SPID...

Meda's acquisition of Recip is concluded

12/13/2007 7:00 AM EST  -   MEDA
Meda's acquisition of Recip AB was announced on 25 October 2007. The acquisition is now concluded. Meda receives product rights and brands, rights to the name Recip, and it takes over existing sales operations. The organisation has around 50 persons; most of them are in marketing and sales. The product portfolio consists of well-established pharmaceuticals such as Kåvepenin®, Heracillin®, Kalcipos®, and TrioBe®. The...

Elekta AB - Six-month interim report May – October 2007/08

12/12/2007 7:00 AM EST  -   Elekta
• Order bookings rose 7 percent to SEK 2,472 M (2,302). Based on unchanged exchange rates or-der bookings rose 12 percent. Order backlog on October 31, 2007 was at an all time high level of SEK 4,425 M. • Net sales rose 9 percent to SEK 2,188 M (2,014). Based on unchanged exchange rates net sales rose 14 percent. • Operating result rose by 23 percent to SEK 195 M (159) and operating margin was 9 percent...

Competition authority approves Meda’s acquisition of Recip

12/7/2007 11:12 AM EST  -   MEDA
The Swedish Competition Authority has announced that nothing hinders Meda from acquiring Recip AB. The acquisition will be completed within short.

NIOX® approved in China. Aerocrine expands its distribution agreement to inclu...

12/7/2007 2:00 AM EST  -   Aerocrine
SOLNA – 7 December 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company’s NIOX product has been approved by SFDA, the Chinese registration authority. Aerocrine has also entered into a distribution agreement with Bioson Inc. that includes sales of both NIOX and NIOX MINO in China.
NIOX is the first device for managing airway inflammation by measuring exhaled NO, that is approved for...

Ortivus AB strenghtens board and management

12/4/2007 8:14 AM EST  -   Ortivus
The Board of Directors of Ortivus AB has appointed board member Jon Risfelt as Deputy Chairman of the Board. The board has further decided to call in Peter Edwall as observer. At the coming annual general shareholders meeting, the election committee intends to propose Jon Risfelt as Chairman of the Board, and Peter Edwall as a Board Member of Ortivus AB

Peter Edwall will, through his extensive experience from the...